Tag: NIH
Vaxxas to develop first room-temperature stable RSV vaccine with NIH license
Vaxxas, a clinical-stage biotechnology company known for its innovative high-density microarray patch (HD-MAP) vaccination platform, has secured a worldwide license from the United States National Institutes of Health (NIH) for a next-generation vaccine antigen aimed at combating Respiratory Syncytial Virus (RSV).
Featured Article
Unlocking growth: Charting midsize manufacturers’ path with digital solutions
According to a recent study by Oxford Economics, midsized companies in the industrial manufacturing sector are setting their eyes on ambitious growth targets. The research, authored in partnership with SAP, revealed that 38% of industry leaders have identified market expansion as their top priority.
